| | ||||||||||
| 1 | INN | Class | Route (list) | PK parameters= Cmax; Tmax; F: bioavailability; t1/2: half-life; VD: volume of distribution; Cl: clearance; PPB: plasma protein binding;(EQN means that value was calculated using VD=(Cl*t1/2)/0.693) | Primary Target and PDB code of Protein-Drug complex | Targets from DrugCentral | Links | |||
| LAPATINIB
| LAPATINIB | ANTINEOPLASTIC AGENTS | ORAL | Cmax 4.18 MICROMOLAR (1.250 MILLIGRAM DAILY)) Tmax 4 HOUR PPB 99 PERCENT HT 14.2 HOUR SOLUBILITY 0.007 MILLIGRAM / MILLILITER | HUMAN EPIDERMAL RECEPTOR TYPE 2 (RECEPTOR TYROSINE-PROTEIN KINASE HER2 ERBB-2 KI = 3 NANOMOLAR) EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR KI = 13 NANOMOLAR) PDB 1XKK (EGFR KINASE DOMAIN COMPLEXED WITH A QUINAZOLINE INHIBITOR- GW572016) LIGAND CODE = FMM (link to the list of PDB complexes) Download experimental 3D coordinates of FMM with added hydrogens | Epidermal growth factor receptor UNIPROT P00533 EGFR -- Receptor tyrosine-protein kinase erbB-2 UNIPROT P04626 ERBB2 more at DrugCentral | EMA | |||
